Ponatinib (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ponatinib" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

4^th place

8^th place

2^nd place

5^th place

low place

low place

34^th place

447^th place

409^th place

7^th place

37^th place

low place

1,569^th place

doi.org

Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, Romero J, Qi J, Chen I, Banda G, Lentini SP, Das S, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Zhou T, Commodore L, Narasimhan NI, Mohemmad QK, Iuliucci J, Rivera VM, Dalgarno DC, Sawyer TK, Clackson T, Shakespeare WC (Junij 2010). »Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant«. J. Med. Chem. 53 (12): 4701–4719. doi:10.1021/jm100395q. PMID 20513156.
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (november 2009). »AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance«. Cancer Cell. 16 (5): 401–412. doi:10.1016/j.ccr.2009.09.028. PMC 2804470. PMID 19878872.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

»Iclusig (ponatinib) Tablets, for Oral Use. Full Prescribing Information«. ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street, Cambridge, MA 02139-4234. Pridobljeno 2. oktobra 2016.

Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, Romero J, Qi J, Chen I, Banda G, Lentini SP, Das S, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Zhou T, Commodore L, Narasimhan NI, Mohemmad QK, Iuliucci J, Rivera VM, Dalgarno DC, Sawyer TK, Clackson T, Shakespeare WC (Junij 2010). »Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant«. J. Med. Chem. 53 (12): 4701–4719. doi:10.1021/jm100395q. PMID 20513156.
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (november 2009). »AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance«. Cancer Cell. 16 (5): 401–412. doi:10.1016/j.ccr.2009.09.028. PMC 2804470. PMID 19878872.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (november 2009). »AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance«. Cancer Cell. 16 (5): 401–412. doi:10.1016/j.ccr.2009.09.028. PMC 2804470. PMID 19878872.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)